Quantbot Technologies LP Has $703,000 Holdings in Teva Pharmaceutical Industries Ltd. $TEVA

Key Points

• Quantbot Technologies LP reduced its stake in Teva Pharmaceutical Industries by 79.8%, now holding 45,754 shares valued at approximately $703,000.
• Teva reported $0.66 earnings per share for the last quarter, surpassing estimates, but had a year-over-year revenue increase of only 0.3%.
• Major institutional investors maintain a significant interest in Teva, with 54.05% of its stock owned by institutional investors and hedge funds.

Quantbot Technologies LP lessened its stake in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Free Report) by 79.8% in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 45,754 shares of the company's stock after selling 180,520 shares during the quarter. Quantbot Technologies LP's holdings in Teva Pharmaceutical Industries were worth $703,000 at the end of the most recent reporting period.

Several other large investors have also added to or reduced their stakes in the business. US Bancorp DE boosted its holdings in Teva Pharmaceutical Industries by 6.5% during the first quarter. US Bancorp DE now owns 10,812 shares of the company's stock worth $166,000 after purchasing an additional 656 shares during the last quarter. Bfsg LLC boosted its holdings in Teva Pharmaceutical Industries by 7.8% during the first quarter. Bfsg LLC now owns 10,960 shares of the company's stock worth $168,000 after purchasing an additional 790 shares during the last quarter. Factorial Partners LLC boosted its holdings in Teva Pharmaceutical Industries by 0.3% during the first quarter. Factorial Partners LLC now owns 333,000 shares of the company's stock worth $5,118,000 after purchasing an additional 1,000 shares during the last quarter. Yousif Capital Management LLC boosted its holdings in Teva Pharmaceutical Industries by 1.9% during the first quarter. Yousif Capital Management LLC now owns 55,986 shares of the company's stock worth $861,000 after purchasing an additional 1,033 shares during the last quarter. Finally, Mackenzie Financial Corp boosted its holdings in Teva Pharmaceutical Industries by 4.1% during the fourth quarter. Mackenzie Financial Corp now owns 29,889 shares of the company's stock worth $659,000 after purchasing an additional 1,171 shares during the last quarter. Institutional investors and hedge funds own 54.05% of the company's stock.

Teva Pharmaceutical Industries Price Performance

Shares of TEVA opened at $18.4660 on Monday. The firm has a market capitalization of $21.18 billion, a PE ratio of -115.41, a PEG ratio of 1.09 and a beta of 0.62. The company's 50-day moving average is $16.75 and its 200-day moving average is $16.27. Teva Pharmaceutical Industries Ltd. has a fifty-two week low of $12.47 and a fifty-two week high of $22.80. The company has a debt-to-equity ratio of 2.45, a current ratio of 1.06 and a quick ratio of 0.77.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last issued its quarterly earnings data on Wednesday, July 30th. The company reported $0.66 earnings per share for the quarter, beating the consensus estimate of $0.64 by $0.02. The company had revenue of $4.18 billion for the quarter, compared to analyst estimates of $4.34 billion. Teva Pharmaceutical Industries had a negative net margin of 0.95% and a positive return on equity of 46.10%. The company's revenue was up .3% on a year-over-year basis. During the same period in the prior year, the firm earned $0.61 earnings per share. Teva Pharmaceutical Industries has set its FY 2025 guidance at 2.500-2.600 EPS. Equities analysts forecast that Teva Pharmaceutical Industries Ltd. will post 2.5 EPS for the current year.

Insider Activity

In other news, insider Placid Jover sold 6,053 shares of the stock in a transaction dated Friday, August 1st. The shares were sold at an average price of $15.16, for a total value of $91,763.48. Following the transaction, the insider directly owned 6,774 shares of the company's stock, valued at $102,693.84. This represents a 47.19% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Eric A. Hughes sold 52,742 shares of the stock in a transaction dated Friday, August 1st. The shares were sold at an average price of $15.16, for a total transaction of $799,568.72. The disclosure for this sale can be found here. Insiders have sold 65,001 shares of company stock valued at $996,958 over the last ninety days. 0.55% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

Several research analysts recently commented on TEVA shares. Truist Financial started coverage on shares of Teva Pharmaceutical Industries in a report on Wednesday, May 28th. They set a "buy" rating and a $25.00 target price for the company. The Goldman Sachs Group started coverage on shares of Teva Pharmaceutical Industries in a research report on Friday, June 6th. They set a "buy" rating and a $24.00 price target on the stock. Bank of America upped their price target on shares of Teva Pharmaceutical Industries from $20.00 to $22.00 and gave the stock a "buy" rating in a research report on Thursday, May 8th. Hsbc Global Res raised shares of Teva Pharmaceutical Industries to a "strong-buy" rating in a research report on Monday, April 28th. Finally, Wall Street Zen raised shares of Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating in a research report on Saturday, July 26th. Two equities research analysts have rated the stock with a Strong Buy rating and six have given a Buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of "Buy" and an average target price of $24.71.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.